Target intelligence / Profile preview

Natural cytotoxicity receptor (NCR) (family: includes NKp30, NKp44, NKp46) (NCR (for the family; NKp46, NKp44, NKp30 for individual members))

Target
NCR (for the family; NKp46, NKp44, NKp30 for individual members)
Molecular classification
Receptor, Immunoglobulin superfamily (each NCR is a type I transmembrane receptor in this family)
01

Overview

Natural cytotoxicity receptors (NCRs) are a family of activating receptors predominantly expressed on natural killer (NK) cells and include NKp46 (NCR1), NKp44 (NCR2), and NKp30 (NCR3). These receptors recognize stress-induced ligands or pathogen-derived molecules primarily on the surface of tumor cells or infected cells, leading to rapid NK cell activation, cytotoxic degranulation (perforin–granzyme pathway), and/or inducement of apoptosis through death ligands such as FasL or TRAIL[1][2][3][4][5]. The coordinated action of NCRs is essential for direct killing of tumors and infected cells, cytokine production, and immune surveillance. The diversity of NCR ligands, alternative receptor isoforms, and tumor evasion strategies highlight both the therapeutic potential and complexity of targeting these receptors in cancer immunotherapy and infectious disease[1][3][4][5]. Note: The queried "target" is incorrectly named as a pathway rather than an individual molecule or receptor. To obtain structured information for actual drug targets, search for one of the major NCR members by canonical name (e.g., "NKp46 (NCR1)", "NKp44 (NCR2)", "NKp30 (NCR3)").

Other names
NCRsnatural killer cell receptorsNKp46 (NCR1)NKp44 (NCR2)NKp30 (NCR3)natural cytotoxicity receptors
02

Mechanism of action

Enhancing NK cell activation and cytotoxicity by upregulating NCR expression or delivering activating signals through NCRs; Blocking inhibitory ligands or preventing NCR ligand shedding for sustained antitumor activity; Fusion of NCR signaling domains to chimeric antigen receptors (CARs) in cell therapy

03

Biological functions

Immune responseCell killing (cytotoxicity)Cytokine productionTumor surveillanceApoptosis induction
04

Disease associations

Cancer (oncology/immunotherapy)Infection (antiviral responses)Inflammation (resolution of inflammatory neutrophil infiltrates)
05

Safety considerations

Off-tumor cytotoxicity (risk of damage to normal tissues expressing NCR ligands)Cytokine release syndrome (if broadly stimulating NK cells)Loss or modulation of ligand expression on tumors can lead to immune escape
06

Interacting drugs

There are no approved small molecule drugs specifically targeting NCRs; most therapeutics are biologics, cellular therapies, or cytokines (e.g., interleukins to modulate NK function). Agents under development include antibodies or engineered cells (CAR-NK) utilizing NCR domains.
07

Biomarkers

NCR surface expression on NK cells (NKp46, NKp30, NKp44)Ligands such as B7-H6 (for NKp30) detected on tumor cells

Beyond the preview

Go deeper on Natural cytotoxicity receptor (NCR) (family: includes NKp30, NKp44, NKp46) (NCR (for the family; NKp46, NKp44, NKp30 for individual members)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Natural cytotoxicity receptor (NCR) (family: includes NKp30, NKp44, NKp46) (NCR (for the family; NKp46, NKp44, NKp30 for individual members)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call